Canadians Living With Dystonia Hope for Access to New Treatment Option Through Public Funding

Canadians Living With Dystonia Hope for Access to New Treatment Option Through Public Funding

                               CDR recommends Dysport Therapeutic™ be reimbursed for reducing the signs and                                                             symptoms of cervical dystonia in adults                     

The Canadian Agency for Drugs and Technologies in Health (CADTH) Common Drug Review (CDR) has recommended that Dysport Therapeutic™ (aboanibotulinumtoxinA) be reimbursed for reducing the subjective symptoms and objective signs of Cervical Dystonia in adults. The Dystonia Medical Research Foundation (DMRF) Canada, on behalf of the dystonia community in Canada,  is hopeful that this new treatment option will soon be accessible through public funding for all patients who could benefit from it.

Please click here for the press release.